

KDA-Asia Pacific region Webinar on the Recent Treatment of Diabetes 2021 <Friday 23 April 2021>

[General information]

Name	Daisuke Yabe
Affiliation Department of Diabetes, Endocrinology and Metabolism, Gifu University Graduate School of Medicine	

[Educational background & professional experience]

Year	Affiliation	Position
1992-1998	Kyoto University Faculty of Medicine (Kyoto, Japan)	MD
1998-2003	University of Texas Southwestern Graduate School of Biomedical Scien (Dallas, Texas, USA)	PhD
2004-2007	Department of Molecular Biology and Medical Chemistry, Kyoto University Graduate School of Medicine (Kyoto, Japan)	Assistant Professor
2007-2016	Center for Diabetes, Endocrinology and Metabolism, Kansai Electric Po- Hospital (Osaka, Japan)	Fellow, Deputy Director, and Director
2011-Present	Division of Molecular and Metabolic Medicine, Kobe University Graduat hool of Medicine (Kobe, Japan)	Visiting Associate Professor, an isiting Professor
2015-Present	Kansai Electric Power Medical Research Institute (Kobe, Japan)	Deputy Director
2016-2018	Department of Diabetes, Endocrinology and Nutrition, Kyoto University (uate School of Medicine (Kyoto, Japan)	Associate Professor
2018-Present	Department of Diabetes, Endocrinology and Metabolism, Gifu University duate School of Medicine (Gifu, Japan)	Professor and Chairman

[Research interests]

Pathophysiology of Asian diabetes; insulin secretion and incretin; medical nutrition therapy

[Selected Recent Publications]

- 1. **Yabe D**, Shiki K, Suzaki K, Meinicke T, Kotobuk Y, Nishida K, Clark D, Yasui A, Seino Y. Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes. BMJ Open (2021) in press.
- 2. Tatsuoka H, Sakamoto S, **Yabe D**, Kabai R, Kato U, Okumura T, Botagarova A, Tokumoto S, Usui R, Ogura M, Nagashima K, Mukai E, Fujitani Y, Watanabe A, Inagaki N. Single-cell Transcriptome Analysis Dissects the Replicating Process of Pancreatic Beta Cells in Partial Pancreatectomy Model. *iScience* (2020) 23(12):101774.
- 3. Seino Y, Kim DJ, **Yabe D**, Tan ECH, Chung WJ, Ha KH, Nangaku M, Node K, Klement R, Yasui A, Lei WY, Lee S, Kyaw MH, Deruaz-Luyet A, Brodovicz KG, Sheu WHH, the EMPRISE East Asia study group. Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study. Endocrinology, Diabetes & Metabolism (2020) 4(1):e00183.
- 4. Tokumoto S, Yabe D, Tatsuoka H, Usui R, Fauzi M, Botagarova A, Goto H, Herrera PL, Ogura M, Inagaki N. Generation and characterization of a novel mouse model that allows spatiotemporal quantification of pancreatic β-cell proliferation. Diabetes (2020) 69(11):2340-2351.
- 5. **Yabe D**, Nakamura J, Kaneto H, Deenadayalan S, Navarria A, Gislum M, Inagaki N, for the PIONEER 10 Investigators. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): a multicentre, openlabel, randomised, phase 3a trial. *Lancet Diabetes & Endocrinology* (2020) 8(5):392-406.